DERMATITIS, ATOPIC
Clinical trials for DERMATITIS, ATOPIC explained in plain language.
Never miss a new study
Get alerted when new DERMATITIS, ATOPIC trials appear
Sign up with your email to follow new studies for DERMATITIS, ATOPIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Eczema drug study halted early: what we learned about GSK1070806
Disease control TerminatedThis study was designed to check the long-term safety of an experimental drug called GSK1070806 for people with moderate to severe eczema (atopic dermatitis). It enrolled 79 adults who had already completed an earlier study of the same drug. The study was terminated early, so res…
Matched conditions: DERMATITIS, ATOPIC
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Eczema drug trial halted early – what we know
Disease control TerminatedThis study tested an experimental drug called JNJ-95475939 in 256 adults with moderate to severe atopic dermatitis (eczema). The goal was to see if the drug could improve skin symptoms like redness, itching, and scaling better than a placebo. The trial was stopped early, so final…
Matched conditions: DERMATITIS, ATOPIC
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Eczema drug trial halted midway – what happened?
Disease control TerminatedThis study tested an injectable drug called GSK1070806 in 161 adults with moderate to severe atopic dermatitis (eczema) who had already tried other treatments. The goal was to see if the drug could reduce eczema severity and itching compared to a placebo. However, the trial was t…
Matched conditions: DERMATITIS, ATOPIC
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New eczema drug abrocitinib tested in everyday use
Disease control TerminatedThis study looked at how well the drug abrocitinib works for adults with moderate to severe atopic dermatitis (eczema) in real-world clinics in Germany. Researchers tracked 112 participants for up to 12 months to see if their skin cleared or improved. The goal was to understand t…
Matched conditions: DERMATITIS, ATOPIC
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC